etodolac at doses in excess of the mean effective dose in osteoarthritis and rheumatoid arthritis caused significantly less microbleeding in normal male volunteers during the seven-day treatment period than the other drugs tested , and not clinically more than that occurring during baseline placebo .
C0059865
etodolac
C0029408
osteoarthritis